| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
YTEN Stock Overview
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada.
Yield10 Bioscience Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.78 |
| 52 Week High | US$10.10 |
| 52 Week Low | US$1.91 |
| Beta | 1.55 |
| 1 Month Change | -27.60% |
| 3 Month Change | -28.90% |
| 1 Year Change | -64.59% |
| 3 Year Change | -92.28% |
| 5 Year Change | -98.35% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| YTEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 25.8% | 5.0% | 2.7% |
| 1Y | -64.6% | -19.5% | -8.1% |
Return vs Industry: YTEN underperformed the US Biotechs industry which returned -19.5% over the past year.
Return vs Market: YTEN underperformed the US Market which returned -8.1% over the past year.
Price Volatility
| YTEN volatility | |
|---|---|
| YTEN Average Weekly Movement | 17.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: YTEN is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: YTEN's weekly volatility has increased from 12% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 29 | Olly Peoples | https://www.yield10bio.com |
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG.
Yield10 Bioscience Fundamentals Summary
| YTEN fundamental statistics | |
|---|---|
| Market Cap | US$13.09m |
| Earnings (TTM) | -US$11.80m |
| Revenue (TTM) | US$567.00k |
24.0x
P/S Ratio-1.2x
P/E RatioIs YTEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YTEN income statement (TTM) | |
|---|---|
| Revenue | US$567.00k |
| Cost of Revenue | US$6.65m |
| Gross Profit | -US$6.08m |
| Other Expenses | US$5.72m |
| Earnings | -US$11.80m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.41 |
| Gross Margin | -1,072.49% |
| Net Profit Margin | -2,081.31% |
| Debt/Equity Ratio | 0% |
How did YTEN perform over the long term?
See historical performance and comparisonValuation
Is Yield10 Bioscience undervalued compared to its fair value and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
1.03x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate YTEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate YTEN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: YTEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: YTEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate YTEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: YTEN is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (1.5x).
Future Growth
How is Yield10 Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
29.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YTEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YTEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YTEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YTEN's revenue (67.4% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: YTEN's revenue (67.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YTEN's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Yield10 Bioscience performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-5.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YTEN is currently unprofitable.
Growing Profit Margin: YTEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YTEN is unprofitable, and losses have increased over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare YTEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YTEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: YTEN has a negative Return on Equity (-89.33%), as it is currently unprofitable.
Financial Health
How is Yield10 Bioscience's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: YTEN's short term assets ($13.4M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: YTEN's short term assets ($13.4M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: YTEN is debt free.
Reducing Debt: YTEN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YTEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: YTEN has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.2% each year.
Dividend
What is Yield10 Bioscience current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate YTEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YTEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YTEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YTEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as YTEN has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.6yrs
Average management tenure
CEO
Olly Peoples (63 yo)
5.58yrs
Tenure
US$1,941,766
Compensation
Dr. Oliver P. Peoples, also known as Olly, Ph D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientifi...
CEO Compensation Analysis
Compensation vs Market: Olly's total compensation ($USD1.94M) is above average for companies of similar size in the US market ($USD771.97K).
Compensation vs Earnings: Olly's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: YTEN's management team is seasoned and experienced (5.6 years average tenure).
Board Members
Experienced Board: YTEN's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: YTEN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Yield10 Bioscience, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Yield10 Bioscience, Inc.
- Ticker: YTEN
- Exchange: NasdaqCM
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$13.086m
- Shares outstanding: 4.90m
- Website: https://www.yield10bio.com
Number of Employees
Location
- Yield10 Bioscience, Inc.
- 19 Presidential Way
- Woburn
- Massachusetts
- 1801
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/18 00:00 |
| End of Day Share Price | 2022/05/18 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.